CDH11 seems therefore to be a promising therapeutic target in RA, because systemic administration of anti-CDH11 antibodies reverses the proliferation and migration of synoviocytes to the sites of joint inflammation, attenuating the symptoms of RA [164] The arthritis drug celecoxib has the structural potential to bind CDH11 and might function as CDH11 antibody-based therapy in clinical trials for RA. Here, CDH11 is linked to arthritic joint disease.